Tyra Biosciences to host conference call on SURF302 initial results
Tyra Biosciences will host a conference call on initial results for oral dabogratinib from the SURF302 Phase 2 study for IR NMIBC on September 9, 2026.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.